2025 Poster Presentations
Poster Session A: (Tuesday-Wednesday morning)
A01: Directed Evolution of Genetically-Encoded Macrocyclic Peptide Drugs, Presented by Zhanna R., Arzanya
A02: Synthesis and Evaluation of PROTAC to Study and Target Protein Kinase CK2, Presented by Marthe D., Centre Leon Berard
A03: Discovery of DS-1093a: An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia, Presented by Takeshi F., Daiichi Sankyo Co., Ltd.
A04: Accelerating Molecular Glue Discovery Through Novel Chemical Space and ASMS Screening, Presented by Hugues L., Edelris SAS
A05: From DEL to Preclinical Models: Discovery and Optimization of a Brain Penetrant MAGL Inhibitor, Presented by Louise P., ETH Zurich
A06: D2B Platform for Rapid PROTAC Synthesis and Testing, Presented by Ellie S., Institute of Cancer Research
A07: Bioisosteres of the Hydrolytic Transition State of Aspartic Protease as Plasmepsin V Inhibitors, Presented by Marija S., Latvian Institute of Organic Synthesis
A08: Single Crystal NMR in Spinning Powders: Towards Label-Free Biomolecular Solid-State NMR, Presented by Rihards A., Latvian Institute of Organic Synthesis
A09: Targeting Anaerobic Pathways of L-Carnitine and γ-Butyrobetaine Metabolism to Suppress Bacterial Trimethylamine Formation, Presented by Raitis B., Latvian Institute of Organic Synthesis
A10: Physical Model Induction with QuanSA™, Presented by Lauren H., Optibrium Ltd.
A11: De-Risking CRBN-Recruiting Degraders: Characterizing Neosubstrate Degradation Specificity and Selectivity, Presented by Kristin R., Promega Corporation
A12: Real-Time Monitoring of Targeted Protein Degradation in Living Cells: Enabling Live-Cell Kinetic Analysis at Every Step, Presented by Alissa K., Promega Corporation
A13: Development of a NanoBRET Probe for Compound Profiling of Live Cell MAGL Inhibition: Accelerating Project Progress in Early Stages of a MAGL Inhibitor Program, Presented by Benjamin B., Roche Pharma
A14: Rational Glue Degrader Identification : A Ligase-Agnostic Platform for Molecular Glue Degrader Discovery, Presented by Stephen Y., Sygnature Discovery
A15: Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease Through Computer-Aided Drug Design, Presented by Atsutoshi O., Takeda Pharmaceutical Co., Ltd.
A16: Rational Design and Computational Evaluation of PROTACs Targeting the Dengue Virus NS3 Protease, Presented by Macarena LP., Universidad Andres Bello
A17: Proteolysis Targeting Chimeras of Casein Kinase 1d (CK1d) for Targeting Circadian Clock Dysfunction in Alzheimer’s Disease (AD), Presented by Ela R., University of Bologna
A18: From Big Data to Smart Fragments: A Knowledge-Guided Approach to Large-Scale Pose Prediction and Library Design, Presented by Joan CM., University of Girona
A19: Plate-Based In Vitro Assays to Evaluate Selectivity of Deubiquitylase (DUB) Inhibitors, Presented by Hirunika P., University of Leeds
A20: Structural and Chemical Biology Investigations into Class I Histone Deacetylase Ubiquitination and Proteasome Mediated Degradation, Presented by Urvashi P., University of Leicester
A21: Development of Highly Specific and Potent Degrader-Antibody Conjugates for Triple-Negative Breast Cancer Treatment: A Step Forward in Precision Cancer Therapy, Presented by Rafaela M., University of Lisbon
A22: An Integrated Platform for the Design, Validation, and Optimization of PROTACs Targeting Epigenetic Regulators, Presented by Inigo AB., University of Navarre
A23: Fragment-Based Discovery of Novel Starting Points for Rational Inhibitor Design Against Fatty Acid Thioesterase A, Presented by Ekaterina K., University of Oxford
A24: Accelerating Molecular Glue Discovery with DNA-Encoded Libraries, Presented by Weiren C., WuXi Apptec Co., Ltd.
A25: Direct-to-Biology (D2B) Accelerates Hit Identification and Optimization, Presented by Weihui G., WuXi Apptec Co., Ltd.
A26: Targeting the Keap1 E3 Ligase: PROTACs with Dual Mechanism of Action, Presented by Anna S., University of Barcelona
Poster Session B: (Wednesday afternoon-Thursday)
B01: D3 Platform: A Deep Drug Discovery Approach to Generating Novel Synthetically-Feasible Lead Molecules, Presented by Marina G., Chemotargets
B02: PADME: A New Context-Specific Drug-Likeness Score for Hit-to-Lead Optimization of Physicochemical and ADME Properties, Presented by Luca M., Chemotargets
B03: Target Occupancy and Selectivity Profiling of Covalent Drugs by Competitive Universal Covalent Probe-Activity-Based Protein Profiling (Ucov-ABPP), Presented by NanC., ChomiX Biotech Co., Ltd.
B04: Targeted Chemoproteomic Screening of Covalent Hits for Challenging Protein Targets in Living Cells, Presented by Richard L., ChomiX Biotech Co., Ltd.
B05: Active Learning FEP Using 3D-QSAR for Prioritizing Bioisosteres in Medicinal Chemistry, Presented by Silvia IT., Cresset
B06: Accelerating Drug Discovery with Physics-Informed Machine Learning, Presented by Garegin P., Deep Origin
B07: Trillion-Scale 3D Search Meets Synthesis-Ready Virtual Space: QIMERA Ultra × eMolecules, Presented by Alexandra G., eMolecules, Inc.
B08: Engineered Enzymes for On-DNA Amide Bond Formation, Presented by Alice L., ETH Zurich
B09: Rapid KD Screening with a Single Measurement Using Flow Induced Dispersion Analysis, Presented by David H., Fida Biosystems ApS
B10: Discovery of New Covalent Cereblon PROTAC Handles, Presented by Henry B., Goethe University
B11: AtomForge High-Throughput: Hit Identification Powered by a Sui generis Force Field, Presented by Anthony F., HTuO Biosciences
B12: An Integrated Discovery Platform for STAT6 Therapeutics: From Biochemical Precision to Translational Relevance, Presented by TJ B., ICE Bioscience, Inc.
B13: QSAR–ML Guided Network Pharmacology for the Identification of Colombian Medicinal Plants With Predicted Anti-Dengue Activity, Presented by Juan SG., Icesi University
B14: Extract2Chip—Bypassing Protein Purification of Challenging Drug Targets for Streamlined Characterization of Protein-Protein Interactions, Presented by Daniel D., Merck KGaA
B15: Identification of a Submicromolar BRD4 PROTAC Degrader from a Moderately Potent DEL Hit: Harnessing the Synergy of DEL and PROTAC Technologies, Presented by Hugues P., Novalix
B16: Integrated Drug Discovery Services from o2h: Advancing Therapeutic Innovation Through Collaborative Research, Presented by Prashant S., o2h
B17: Investigation of Non-Degraded PROTAC Targets with CETSA, Presented by Erwin B., Pelago Bioscience AB
B18: Structure-Based Discovery of DARPin Binders and Their Complexes with Drug Target Proteins, Presented by Jiwon K., POSTECH
B19: Rational Design and Experimental Validation of a Modulatory Nanobody Targeting the TRPM4 Ion Channel, Presented by Ingrid AD., Universidad Andres Bello
B20: Machine Learning-Guided Rational Design of Species-Specific SET-M33 Analogs Targeting ESKAPE Pathogens, Presented by Ismael C., University of Stavanger
B21: Medicinal Chemistry Self-Driving Lab - Accelerating Hit Optimisation with Direct to Biology Approach, Presented by Santha S., University of Toronto
B22: Linking ATP and Allosteric Sites in EGFR: Structure-Activity Insights into Inactive-Conformation Binding Inhibitors, Presented by Mareike M., University of Tubingen
B23: DELs in Cells – Integral Membrane Screening, Presented by Leif L., Vipergen ApS
B24: DNA-Encoded Libraries and Display Technologies Empower Early Discovery of Peptide Drugs and Peptide-Based Delivery Tools, Presented by Rhys T., WuXi Apptec Co., Ltd.
B25: Streamlined Solutions from Novel E3 Target to Functional PROTAC, Presented by Wenji S., WuXi Apptec Co., Ltd.
B26: Unraveling PROTAC Mechanisms: From DEL Screening to Cellular Degradation Through Biophysical Profiling, Presented by Alice S., Dynamic Biosensors GmbH